Clinical trial

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

NCT06910072

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimab Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

Design: INTERVENTIONAL · Status: ENROLLING BY INVITATION · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusENROLLING_BY_INVITATION

Study typeINTERVENTIONAL

Start date2025-07-21

PhasePHASE2 / PHASE3

Conditions

Triple-Negative Breast Cancer (TNBC)unresolved

Neoadjuvant Therapyunresolved

Interventions

paclitaxel polymeric micelles + carboplatin + iparomilimab and tuvonralimabDRUG

Sponsors & collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Scienceslead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06910072 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.